Dr. Joshua Grill, Assistant Professor of Neurology and Director of Education for the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, was featured in several outlets regarding his research showing that the outcome of any Alzheimer's clinical trial can be influenced by who the patient's study partner is, whether it's a spouse, adult child, or "other." Coverage included Dec. 19 in the Examiner.com and Science Daily; Dec. 20 in MedPage Today; and Dec. 21 in NewsMedical.net and Labmate Online.
Dr. John Ringman, Associate Clinical Professor of Neurology, David Geffen School of Medicine at UCLA, and Associate Clinical Director, Mary S. Easton Center for Alzheimer's Disease Research at UCLA was quoted Dec. 13 in a LA Times article about a possible therapeutic drug, which will begin the five-year clinical trial next Spring in Yarumal, Colombia. The name of this drug trial is called Alzheimer's Prevention Initiative. Dr. Ringman and his group will also be enrolling subjects in this study at the Easton Center at UCLA.
Dr. David B. Teplow, Professor of Neurology and Interim Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, was quoted Nov. 28 in a Chicago Tribune story about a study that used a human gene in mice to more accurately measure the damage caused by Alzheimer's disease.
Asian News International reported Nov. 18 on research in which Dr. Gal Bitan, Associate Professor of Neurology at UCLA, and colleagues used an innovative compound known as a "molecular tweezer" in a mouse model to break up the toxic aggregations of proteins that afflict the brain in Alzheimer's disease. Bitan was quoted.
Dr. Gal Bitan, Associate Professor in Residence of Neurology, David Geffen School of Medicine at UCLA, was featured in the Nov. 15 Examiner.com about his development of a molecular compound dubbed a "tweezer" that, in a living mouse model of Alzheimer's, for the first time cleared the toxic proteins that have been linked to Alzheimer's disease.